Susan M. Cook

Evidence for a Significant Role of α3-Containing GABAA Receptors in Mediating the Anxiolytic Effects of Benzodiazepines

The GABAA receptor subtypes responsible for the anxiolytic effects of nonselective benzodiazepines (BZs) such as chlordiazepoxide (CDP) and diazepam remain controversial. Hence, molecular genetic data suggest that α2-rather than α3-containing GABAA receptors are responsible for the anxiolytic effects of diazepam, whereas the anxiogenic effects of an α3-selective inverse agonist suggest that an agonist selective for this subtype should be anxiolytic. We have extended this latter pharmacological approach to identify a compound, 4,2′-difluoro-5′-[8-fluoro-7-(1-hydroxy-1-methylethyl)imidazo[1,2-á]pyridin-3-yl]biphenyl-2-carbonitrile (TP003), that is an α3 subtype selective agonist that produced a robust anxiolytic-like effect in both rodent and non-human primate behavioral models of anxiety. Moreover, in mice containing a point mutation that renders α2-containing receptors BZ insensitive (α2H101R mice), TP003 as well as the nonselective agonist CDP retained efficacy in a stress-induced hyperthermia model. Together, these data show that potentiation of α3-containing GABAA receptors is sufficient to produce the anxiolytic effects of BZs and that α2 potentiation may not be necessary.

Anxiogenic properties of an inverse agonist selective for α3 subunit‐containing GABAA receptors

1 α3IA (6‐(4‐pyridyl)‐5‐(4‐methoxyphenyl)‐3‐carbomethoxy‐1‐methyl‐1H‐pyridin‐2‐one) is a pyridone with higher binding and functional affinity and greater inverse agonist efficacy for GABAA receptors containing an α3 rather than an α1, α2 or α5 subunit. If doses are selected that minimise the occupancy at these latter subtypes, then the in vivo effects of α3IA are most probably mediated by the α3 subtype. 2 α3IA has good CNS penetration in rats and mice as measured using a [3H]Ro 15‐1788 in vivo binding assay. 3 At doses in rats that produce relatively low levels of occupancy (12%) in the cerebellum (i.e. α1‐containing receptors), α3IA (30 mg kg−1 i.p.), like the nonselective partial inverse agonist N‐methyl‐β‐carboline‐3‐carboxamide (FG 7142), not only caused behavioural disruption in an operant, chain‐pulling assay but was also anxiogenic in the elevated plus maze, an anxiogenic‐like effect that could be blocked with the benzodiazepine antagonist Ro 15‐1788 (flumazenil). 4 Neurochemically, α3IA (30 mg kg−1 i.p.) as well as FG 7142 (15 mg kg−1 i.p.) increased the concentration of the dopamine metabolite 3,4‐dihydroxyphenylacetic acid in rat medial prefrontal cortex by 74 and 68%, respectively, relative to vehicle‐treated animals, a response that mimicked that seen following immobilisation stress. 5 Taken together, these data demonstrate that an inverse agonist selective for GABAA receptors containing an α3 subunit is anxiogenic, and suggest that since α3‐containing GABAA receptors play a role in anxiety, then agonists selective for this subtype should be anxiolytic.

In Vitro and In Vivo Inhibition of Inositol Monophosphatase by the Bisphosphonate L‐690,330

Abstract: We have previously described the synthesis of bis‐phosphonate‐containing inhibitors of inositol monophosphatase. In the present study, a more detailed examination of the in vitro and in vivo properties of one of these compounds, L‐690,330, is described. L‐690,330 is a competitive inhibitor of inositol monophosphatase with a K1, depending on the source of IMPase, of between 0.2 and 2 μM. Although ∼1,000‐fold more potent in vitro than lithium, in muscarinic m1 receptor‐transfected Chinese hamster ovary cells prelabelled with [3H]inositol, L‐690,330 only produced 40% of the accumulation of [3H]inositol monophosphates achieved by lithium at the same concentration (10 mM), suggesting that the ability of L‐690,330 to cross the cell membrane is limited. Nevertheless, under conditions of cholinergic stimulation (100 mg/kg of pilocarpine s.c.), high doses of L‐690,330 were able to increase brain inositol(1)phosphate levels in vivo to three‐ to fourfold control levels. This effect was dose dependent (ED50= 0.3 mmol/kg s.c.) and was maximal after 1 h. In peripheral tissues, the effects of L‐690,330 on inositol(1)phosphate levels mimicked those of lithium both qualitatively and quantitatively. However, in the brain, the effects of L‐690,330 were much less than seen with lithium, consistent with the blood‐brain barrier restricting access of the polar L‐690,330 into the CNS, thereby further limiting entry of compound into cells in the brain. In the future, it may be possible to develop prodrugs of this compound, which circumvent many of the cell permeability problems inherent in bisphosphonate compounds.

Generation and Characterisation of Stable Cell Lines Expressing Recombinant Human N-Methyl-d-Aspartate Receptor Subtypes

Abstract: Transfection of mouse L(tk‐) cells with human N‐methyl‐d‐aspartate (NMDA) receptor subunit cDNAs under the control of a dexamethasone‐inducible promoter has been used to generate two stable cell lines expressing NR1a/NR2A receptors and a stable cell line expressing NR1a/NR2B receptors. The cell lines have been characterised by northern and western blot analyses, and the pharmacology of the recombinant receptors determined by radioligand binding techniques. Pharmacological differences were identified between the two NMDA receptor subtypes. The glutamate site antagonist d,l‐(ε)‐2‐[3H]amino‐4‐propyl‐5‐phosphono‐3‐pentanoic acid ([3H]CGP 39653) had high affinity for NR1a/NR2A receptors (KD = 3.93 nM) but did not bind to NR1a/NR2B receptors. Glycine site agonists showed a 2.6–5.4‐fold higher affinity for NR1a/NR2B receptors. Data from radioligand binding studies indicated that one of the cell lines, NR1a/NR2A‐I, expressed a stoichiometric excess of the NR1a subunit, which may exist as homomeric assemblies. This observation has implications when interpreting data from pharmacological analysis of recombinant receptors, as well as understanding the assembly and control of expression of native NMDA receptors.

Comparison of in vivo and ex vivo [3H]flumazenil binding assays to determine occupancy at the benzodiazepine binding site of rat brain GABAA receptors

In the present study, the occupancy of flumazenil (Ro 15-1788; 1-30mg/kg p.o.) at the benzodiazepine site of rat brain GABA(A) receptors was compared using in vivo and ex vivo binding methodologies with [(3)H]flumazenil as the radioligand. Animals either received tracer quantities of [(3)H]flumazenil 3min before being killed for the in vivo binding, or were killed and brain homogenates incubated with 1.8nM [(3)H]flumazenil. The flumazenil dose required to inhibit in vivo binding of [(3)H]flumazenil by 50% (ID(50)) was 2.0mg/kg, which represents the most accurate measure of benzodiazepine site occupancy by flumazenil in vivo. Occupancy measured in crude brain homogenates using the ex vivo method was time dependent with a 3mg/kg dose giving occupancies of 77% and 12% using 0.5 or 60min ex vivo incubations times, respectively, presumably due to dissociation from the binding site during the ex vivo incubation. When incubation time was minimised (0.5min), and despite being under non-equilibrium conditions, the ex vivo method gave an ID(50) of 1.5mg/kg which was not too dissimilar from that observed using in vivo binding (2.0mg/kg). As expected, ex vivo binding can give an underestimation of receptor occupancy but this can be minimised by careful attention to the kinetics of unlabelled drug and radioligand.

Measurement of lithium-induced changes in mouse inositol(1)phosphate levels in vivo

Abstract: An anion‐exchange HPLC mass assay was used to characterize Swiss‐Webster mouse brain and peripheral tissue inositol(1)phosphate [Ins(1)P] levels. Ins(1)P was identified in all tissues studied but Ins(4)P could be identified only in brain, and then only as a part of a peak containing an additional, unidentified component. As a result, it was not possible to quantify Ins(4)P levels. Following a single subcutaneous dose of lithium (10 mmol/kg), brain Ins(1)P levels were maximally elevated after 6 h (corresponding to peak brain lithium concentrations) and were increased to levels 35‐ and 20‐fold higher than in saline‐treated animals in cholinergic agonist (pilocarpine)‐stimulated and unstimulated animals, respectively. The ED50 for the lithium‐induced accumulation of brain Ins(1)P 6 h after administration was 4–6 mmol/kg. The pilocarpine stimulation of lithium‐induced brain Ins(1)P accumulation had an ED50 of 22 mg/kg, with maximal accumulation occurring 120 min after pilocarpine administration. Atropine reduced Ins(1)P levels, in both the absence and the presence of lithium, by 40%, indicating that cholinergic systems contribute a large (40%) component of basal brain phosphatidylinositol (PI) cycle activity. In peripheral tissues, there were lithium‐induced accumulations of Ins(1)P in kidney, heart, and liver (but not testes) but these were less than that seen in the brain, suggesting that under basal (and pilocarpine‐stimulated) conditions, the brain has a higher turnover of the PI cycle than the various peripheral tissues studied. These data support the hypothesis that lithium exerts its effects in vivo via modulation of the PI cycle. In addition, the susceptibility of brain rather than peripheral tissue to the pharmacological effects of lithium may be a consequence of higher PI cycle turnover in brain.

RAT PHARMACOKINETICS AND PHARMACODYNAMICS OF A SUSTAINED RELEASE FORMULATION OF THE GABAA α5-SELECTIVE COMPOUND L-655,708

The pharmacokinetic and pharmacodynamic (i.e., receptor occupancy) properties of L-655,708, a compound with selectivity for α5-over α1-, α2-, and α3-containing GABAA receptors, were examined in rats with the aim of developing a formulation that would give sustained (up to 6 h) and selective occupancy of α5-containing GABAA receptors suitable for behavioral studies. Standard rat pharmacokinetic analyses showed that L-655,708 has a relatively short half-life with kinetics in the brain mirroring those in the plasma. In vivo binding experiments showed that plasma concentrations of around 100 ng/ml gave relatively selective in vivo occupancy of rat brain α5-versus α1-, α2-, and α3-containing GABAA receptors. Therefore, this plasma concentration was chosen as a target to achieve relatively selective occupancy of α5-containing receptors using s.c. implantations of L-655,708 (0.4, 1.5, or 2.0 mg) formulated into tablets of various size (20 or 60 mg) containing different amounts of L-655,708 and combinations of low and high viscosity hydroxypropyl methylcellulose (LV- and HV-HPMC). The optimum formulation, 1.5 mg of L-655,708 compressed into a 60-mg tablet with 100% HV-HPMC, resulted in relatively constant plasma concentrations being maintained for at least 6 h with very little difference between Cmax concentrations (125–150 ng/ml) and plateau concentrations (100–125 ng/ml). In vivo binding experiments confirmed the selective occupancy of rat brain α5-over α1-, α2-, and α3-containing GABAA receptors.

In vivo labelling of α5 subunit-containing GABAA receptors using the selective radioligand [3H]L-655,708

L-655,708 is an imidazobenzodiazepine possessing 30-70-fold selectivity for the benzodiazepine binding site of GABA(A) receptors containing an alpha5 rather than alpha1, alpha2 or alpha3 subunit. In the present study, [(3)H]L-655,708 was used to label mouse brain benzodiazepine binding sites in vivo. When compared to inhibition of in vivo binding of the non-selective ligand [(3)H]Ro 15-1788, the pharmacology of mouse in vivo [(3)H]L-655,708 binding was consistent with selective in vivo labelling of alpha5 subunit-containing GABA(A) receptors. Thus, diazepam was equipotent at inhibiting in vivo [(3)H]L-655,708 and [(3)H]Ro 15-1788 binding; zolpidem, which has very low affinity for alpha5-containing GABA(A) receptors, gave no inhibition of in vivo [(3)H]L-655,708 binding despite inhibiting in vivo [(3)H]Ro 15-1788 binding; and L-655,708 was more potent at inhibiting the in vivo binding of [(3)H]L-655,708 compared to [(3)H]Ro 15-1788. This pharmacological specificity of in vivo [(3)H]L-655,708 binding was confirmed autoradiographically. Hence, the anatomical distribution of in vivo [(3)H]L-655,708 binding was comparable to the distribution of alpha5-containing GABA(A) receptors identified in vitro. Moreover, this distribution was distinct from that identified using [(3)H]Ro 15-1788. These data therefore suggest that [(3)H]L-655,708 can be used to identify alpha5-containing GABA(A) receptors in vivo and that this ligand can be used to measure receptor occupancy of alpha5-selective ligands.

Kindling induced by pentylenetetrazole in rats is not directly associated with changes in the expression of NMDA or benzodiazepine receptors

Repeated injections of a subconvulsant dose of pentylenetetrazole (PTZ, 30 mg/kg IP three times weekly for 13 injections) in Wistar and hooded Lister rats resulted in kindled seizures, the extent of which varied between strains. Wistar rats achieved stage 4 of clonic-tonic seizures, whereas hooded Lister rats only reached stage 2 of convulsive waves axially through the body. Rats were killed 10 days after their final injection, and radioligand binding was used to measure the expression of NMDA receptors in cortex and hippocampus using [3H]MK-801 and [3H]L-689,560, the latter binding specifically to the NR1 subunit. [3H]Ro 15-1788 measured expression of GABA(A)-benzodiazepine binding sites containing alpha1, alpha2, alpha3, or alpha5 subunits. Specific analysis of GABA(A) receptors containing the alpha5 subunit, which are preferentially localized in the hippocampus, was assessed with [3H]L-655,708. In the cortex, there was no effect of strain or treatment on the K(D) or B(max) of any of the ligands. Similarly, there was no effect of strain or treatment on hippocampal [3H]L-689,560 or [3H]Ro 15-1788 binding. However, in the hippocampus there was a significant, albeit modest, effect of treatment on the B(max) of [3H]MK-801 binding and the B(max) and K(D) of [3H]L-655,708 binding, i.e., PTZ-treated rats had fewer [3H]MK-801 and [3H]L-655,708 binding sites (NMDA and alpha5-containing GABA(A) receptors, respectively), but, these reductions were significant only in the relatively seizure-insensitive hooded Lister strain. This suggests that the increased susceptibility to kindling in Wistar rats is not directly related to alterations in the expression of NMDA or GABA(A) receptors.

Selective labelling of diazepam-insensitive GABAA receptors in vivo using [3H]Ro 15-4513

Classical benzodiazepines (BZs), such as diazepam, bind to GABAA receptors containing α1, α2, α3 or α5 subunits that are therefore described as diazepam‐sensitive (DS) receptors. However, the corresponding binding site of GABAA receptors containing either an α4 or α6 subunit do not bind the classical BZs and are therefore diazepam‐insensitive (DIS) receptors; a difference attributable to a single amino acid (histidine in α1, α2, α3 and α5 subunits and arginine in α4 and α6). Unlike classical BZs, the imidazobenzodiazepines Ro 15‐4513 and bretazenil bind to both DS and DIS populations of GABAA receptors. In the present study, an in vivo assay was developed using lorazepam to fully occupy DS receptors such that [3H]Ro 15‐4513 was then only able to bind to DIS receptors. When dosed i.v., [3H]Ro 15‐4513 rapidly entered and was cleared from the brain, with approximately 70% of brain radioactivity being membrane‐bound. Essentially all membrane binding to DS+DIS receptors could be displaced by unlabelled Ro 15‐4513 or bretazenil, with respective ID50 values of 0.35 and 1.2 mg kg−1. A dose of 30 mg kg−1 lorazepam was used to block all DS receptors in a [3H]Ro 15‐1788 in vivo binding assay. When predosed in a [3H]Ro 15‐4513 binding assay, lorazepam blocked [3H]Ro 15‐4513 binding to DS receptors, with the remaining binding to DIS receptors accounting for 5 and 23% of the total (DS plus DIS) receptors in the forebrain and cerebellum, respectively. The in vivo binding of [3H]Ro 15‐4513 to DIS receptors in the presence of lorazepam was confirmed using α1H101R knock‐in mice, in which α1‐containing GABAA receptors are rendered diazepam insensitive by mutation of the histidine that confers diazepam sensitivity to arginine. In these mice, and in the presence of lorazepam, there was an increase of in vivo [3H]Ro 15‐4513 binding in the forebrain and cerebellum from 4 and 15% to 36 and 59% of the total (i.e. DS plus DIS) [3H]Ro 15‐4513 binding observed in the absence of lorazepam.